Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Clinical Pearls I
- Outcome data should support the use of any expensive test
- Data does not exist to support the routine use of MRI in DCIS patients and invasive breast cancer patients
Clinical Pearls II
- It would be beneficial to have guidelines for the appropriate use of MRI
- Currently, the use of MRI is largely dependent on the surgeon and institution
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More